Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Amicus Therapeutics, Inc. (FOLD) had Revenue of $528.29M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$528.29M
Net Income	$-56.11M
Cost of Goods Sold	$52.94M
Gross Profit	$475.35M
Operating Expenses	$503.42M
Operating Income	$24.88M
Non-Operating Income/Expense	$-53.63M
Pre-Tax Income	$-28.76M
Normalized Pre-Tax Income	$-28.76M
Income after Taxes	$-56.11M
Income from Continuous Operations	$-56.11M
Consolidated Net Income/Loss	$-56.11M
Normalized Income after Taxes	$-56.11M
EBIT	$24.88M
EBITDA	$35.69M
Weighted-Average Shares Outstanding (Basic)	304.38M
Weighted-Average Shares Outstanding (Diluted)	304.38M
Earnings per Share (EPS) (Basic)	$-0.18
Earnings per Share (EPS) (Diluted)	$-0.18
Balance Sheet Financials
Current Assets	$504.74M
Property, Plant, and Equipment	$29.38M
Long-Term Assets	$280.30M
Total Assets	$785.03M
Current Liabilities	$148.70M
Long-Term Debt	$390.11M
Long-Term Liabilities	$442.29M
Total Liabilities	$590.99M
Common Equity	$194.05M
Tangible Shareholders Equity	$-20.95M
Shareholders Equity	$194.04M
Common Shares Outstanding	299.04M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-33.89M
Cash Flow from Investing Activities	$-0.56M
Cash Flow from Financial Activities	$5.12M
Beginning Cash	$250.08M
End Cash	$216.72M
Increase/Decrease in Cash	$-33.36M
Stock-Based Compensation	$84.91M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.39
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.67
Debt to Equity Ratio	2.01
Gross Margin	89.98%
Operating Margin	4.71%
EBIT Margin	4.71%
EBITDA Margin	6.75%
Pre-Tax Profit Margin	-5.44%
Profit Margin	-10.62%
Free Cash Flow	$-37.44M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.67
Inventory Turnover	0.45
Receiveable Turnover	5.23
Days Sales in Receivables	69.85
Return on Equity	-28.91%
Return on Tangible Equity	267.81%
Return on Assets	-7.15%
Return on Investments	-9.60%
Book Value Per Share	$0.65
Free Cash Flow per Share	$-0.12
Operating Cash Flow per Share	$-0.11

Data from Zacks Investment Research, Inc.